Skip to main content
TITAN PHARMACEUTICALS INC logo

TITAN PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · TTNP ISIN · US8883146065 LEI · 549300NOUZGB2ZNVJ794 US Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2020-01-31 Proxy Solicitation & In…
Country US United States of America
Listing US TTNP

About TITAN PHARMACEUTICALS INC

https://www.titanpharm.com/

Titan Pharmaceuticals, Inc. is a development-stage biopharmaceutical company that develops proprietary therapeutics using its clinically proven ProNeura® technology, a long-term, continuous drug delivery platform. This platform is designed for the administration of medicines to treat select chronic diseases. The ProNeura system involves a small, solid implant that is placed subdermally and provides continuous, non-fluctuating blood levels of a drug for an extended period. The company's development efforts have historically focused on treatments for central nervous system disorders.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2020-01-31 English
TITAN PHARMACEUTICALS, INC.
Major Shareholding Notification
2020-01-27 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC, as indicated by the header and form type 'PRE 14A'. It is a proxy solicitation document related to a special meeting of stockholders of Titan Pharmaceuticals, Inc. The purpose of the meeting is to approve a reverse stock split and related corporate actions. The text includes detailed information about the meeting date, voting procedures, record date, and the specific proposal to amend the certificate of incorporation for the reverse split. This type of document is used to solicit shareholder votes and provide information necessary for shareholders to make informed voting decisions. It is not a report of voting results, nor is it a financial report or earnings release. It is not a notice of dividend, nor a management or board change announcement. It is a proxy solicitation document, which corresponds to the category 'Proxy Solicitation & Information Statement' (PSI). The document length (15,000 characters) and content confirm it is the proxy statement itself, not just an announcement of its availability.
2020-01-22 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically discusses the submission of matters to a vote of security holders, detailing the outcome of a vote on a reverse stock split proposal at an annual meeting. It states that the proposal did not receive the necessary vote and that the meeting was adjourned and then canceled, with plans to seek approval at a later date. This matches the description of a Declaration of Voting Results & Voting Rights Announcement, as it reports official results from a shareholder vote. The document length is 3908 characters, which is relatively short but contains substantive information about the vote results, not just an announcement of a report. Therefore, the appropriate classification is DVA (Declaration of Voting Results & Voting Rights Announcements).
2020-01-16 English
SABBY 13G-A TTNP 1.13.20
Major Shareholding Notification
2020-01-13 English
Regulatory Filings 2020
Regulatory Filings
2020-01-09 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.